Prescription Digital Therapeutics: An Emerging Treatment Option for Negative Symptoms in Schizophrenia
- PMID: 38960019
- PMCID: PMC11410508
- DOI: 10.1016/j.biopsych.2024.06.026
Prescription Digital Therapeutics: An Emerging Treatment Option for Negative Symptoms in Schizophrenia
Abstract
Digital therapeutics-web-based programs, smartphone applications, and wearable devices designed to prevent, treat, or manage clinical conditions through software-driven, evidence-based intervention-can provide accessible alternatives and/or may supplement standard care for patients with serious mental illnesses, including schizophrenia. In this article, we provide a targeted summary of the rapidly growing field of digital therapeutics for schizophrenia and related serious mental illnesses. First, we define digital therapeutics. Then, we provide a brief summary of the emerging evidence of the efficacy of digital therapeutics for improving clinical outcomes, focusing on potential mechanisms of action for addressing some of the most challenging problems, including negative symptoms of psychosis. Our focus on these promising targets for digital therapeutics, including the latest in prescription models in the commercial space, highlights future directions for research and practice in this exciting field.
Keywords: Digital health; Digital therapeutics; Mobile health; Psychosis; Psychosocial treatments; Schizophrenia.
Copyright © 2024 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Prescription Digital Therapeutics for Substance Use Disorder in Primary Care: Mixed Methods Evaluation of a Pilot Implementation Study.JMIR Form Res. 2024 Sep 2;8:e59088. doi: 10.2196/59088. JMIR Form Res. 2024. PMID: 39222348 Free PMC article.
-
Application of blended care as a mechanism of action in the construction of digital therapeutics.Einstein (Sao Paulo). 2020 Nov 20;18:eMD5640. doi: 10.31744/einstein_journal/2020MD5640. eCollection 2020. Einstein (Sao Paulo). 2020. PMID: 33237249 Free PMC article.
-
A new window into psychosis: The rise digital phenotyping, smartphone assessment, and mobile monitoring.Schizophr Res. 2018 Jul;197:67-68. doi: 10.1016/j.schres.2018.01.005. Epub 2018 Jan 12. Schizophr Res. 2018. PMID: 29338959
-
Developing digital interventions for people living with serious mental illness: perspectives from three mHealth studies.Evid Based Ment Health. 2017 Nov;20(4):98-101. doi: 10.1136/eb-2017-102765. Epub 2017 Oct 12. Evid Based Ment Health. 2017. PMID: 29025862 Free PMC article. Review.
-
The New Emerging Treatment Choice for Major Depressive Disorders: Digital Therapeutics.Adv Exp Med Biol. 2024;1456:307-331. doi: 10.1007/978-981-97-4402-2_16. Adv Exp Med Biol. 2024. PMID: 39261436 Review.
Cited by
-
Digital therapeutics for cognitive impairments associated with schizophrenia: our opinion.Front Psychiatry. 2025 Apr 17;16:1535309. doi: 10.3389/fpsyt.2025.1535309. eCollection 2025. Front Psychiatry. 2025. PMID: 40313239 Free PMC article. No abstract available.
References
-
- Haddock G, Eisner E, Boone C, Davies G, Coogan C, Barrowclough C (2014): An investigation of the implementation of NICE-recommended CBT interventions for people with schizophrenia. J Ment Health Abingdon Engl 23: 162–165. - PubMed
-
- Reist C, Valdes E, Ren Y, Wright A, Rubio JM (2021): Using Claims Data to Assess Treatment Quality of First-Episode Psychosis. Psychiatr Serv Wash DC 72: 247–253. - PubMed
-
- Workforce Tracker Finds Large Variation in Healthcare Providers Offering Behavioral Health Services Nationwide | Milken Institute School of Public Health | The George Washington University (n.d.): Milken Institute School of Public Health. Retrieved March 19, 2024, from https://publichealth.gwu.edu/workforce-tracker-finds-large-variation-hea...
-
- Satiani A, Niedermier J, Satiani B, Svendsen DP (2018): Projected Workforce of Psychiatrists in the United States: A Population Analysis. Psychiatr Serv Wash DC 69: 710–713. - PubMed
Publication types
MeSH terms
Grants and funding
- P01 AA029546/AA/NIAAA NIH HHS/United States
- R21 DA057535/DA/NIDA NIH HHS/United States
- R01 MH125426/MH/NIMH NIH HHS/United States
- R01 MH122367/MH/NIMH NIH HHS/United States
- UG1 DA040309/DA/NIDA NIH HHS/United States
- P30 DA029926/DA/NIDA NIH HHS/United States
- UG1 DA013035/DA/NIDA NIH HHS/United States
- UG1 DA040316/DA/NIDA NIH HHS/United States
- R21 MH124095/MH/NIMH NIH HHS/United States
- R01 MH127265/MH/NIMH NIH HHS/United States
- T32 DA037202/DA/NIDA NIH HHS/United States
- U01 DA047982/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical